title: Successful treatment of hereditary angioedema with bradykinin B2-receptor antagonist icatibant.
abstract: The bradykinin B2 receptor antagonist icatibant has recently become available for treating hereditary angioedema. Our observations demonstrate icatibant to be effective and safe for the treatment of both, abdominal and cutaneous attacks in a practice setting beyond clinical studies.
authors.affiliation: Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité-Universitätsmedizin Berlin, Germany.
authors.forename: Karoline
authors.initials: K
authors.lastname: Krause
authors.forename: Martin
authors.initials: M
authors.lastname: Metz
authors.forename: Torsten
authors.initials: T
authors.lastname: Zuberbier
authors.forename: Marcus
authors.initials: M
authors.lastname: Maurer
authors.forename: Markus
authors.initials: M
authors.lastname: Magerl
mesh_terms: D000328:Adult; D054179:Angioedemas, Hereditary / Q000188:drug therapy* / Q000473:pathology*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage; D001920:Bradykinin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D065168:Bradykinin Receptor Antagonists; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D065168:Bradykinin Receptor Antagonists; C065679:icatibant; D001920:Bradykinin